Biohit Oyj

Report Publication Announcement • Apr 26, 2017

Disclosure 351592

Biohit Oyj - Decisions of general meeting

Decisions of the Annual General Meeting of Biohit Oyj

Biohit Oyj Decisions of general meeting April 26, 2017 at 7:30 pm local time (EEST)

The Annual General Meeting (AGM) of Biohit Oyj held on Wednesday April 26, 2017 approved the financial statements of the parent company and the consolidated financial statements, and discharged the members of the Board of Directors and the President and CEO from liability for the financial year 2016.

Distribution of dividends

The AGM approved the Board of Directors proposal that no dividend shall be paid for the financial period ended on December 31, 2016.

Members of the Board of Directors

The AGM decided that the number of members of the Board of Directors would be five (5) and elected the following Board members until the end of the next AGM: Professor (h.c.) Osmo Suovaniemi, CEO Franco Aiolfi, emeritus professor Matti Härkönen, professor Stina Syrjänen and Commercial Counsellor Eero Lehti.

Additionally, the AGM decided that the Chairman of the Board of Directors would be paid a meeting fee of EUR 1,500 and the other Board members would be paid a meeting fee of EUR 1,500.

Election and remuneration of the Auditor

The AGM elected authorized public accountants PricewaterhouseCoopers Oy as the company’s auditor until the end of the next AGM. The auditor will be paid remuneration against the auditor’s invoice.

All decisions of the AGM were made unanimously. The minutes of the AGM will be available for review by shareholders by May 2, 2017 on the company’s website (www.biohithealthcare.com /investors) and at the corporate headquarters of Biohit, located at Laippatie 1, 00880 Helsinki.

Additional information:

CEO Semi Korpela, Biohit Oyj

tel. +358 9 773 861

investor.relations@biohit.fi

www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com